Cross Border Biotech Blog

Bloom Burton & Co. is Canada's leading biotechnology and healthcare-specialized investment banking firm, which exists to accelerate returns in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial approach, leads to the right monetization events for companies and investors. Bloom Burton provides capital raising, M&A advisory, equity research, management consulting, direct investments through equity and debt funds, and company creation services.

Visit Blog

Authors

Wayne Schnarr

Wayne Schnarr advises Bloom Burton in the areas of corporate strategy, capital markets and pharmaceutical product commercialization. For more than 30 years, Wayne has assessed hundreds of technologies, products, business plans and companies in the biotechnology, pharmaceutical and financial sectors. He has been involved in industrial process development, manufacturing of biologics and diagnostics, licensing, and policy formation. In the financial sector, Wayne was an analyst with four Canadian securities dealers, a founder and partner in the venture management firm BioCatalyst Yorkton, and leader of the healthcare investor relations team at The Equicom Group, and has served as a biotechnology company officer and director.

Brian Bloom

Brian Bloom is a co-founder of Bloom Burton & Co. and serves as the firm’s President and Head of Institutional Sales. Brian is a member of the Life Sciences Advisory Board at the National Research Council of Canada and also serves on the Board of Directors at BIOTECanada, the Baycrest Foundation. Brian is also the Chairman of the Board of Triumvira Immunologics and Appili Therapeutics and on the Board of Directors of Grey Wolf Animal Health and Qing Bile Therapeutics. Brian started his career at New York-based investment banking firms SCO Financial Group and Molecular Securities. Brian received an Honors Bachelor of Science in Biochemistry from McMaster University and subsequently studied at the Mount Sinai Graduate School for Biological Sciences of New York University, with a focus in molecular endocrinology and biophysics.

Awards & Publications

** He writes most frequently for blog

Latest Articles

Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares Original press release here VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc...

Appili Therapeutics Names Dr. Armand Balboni as Chief Executive Officer

Appili Therapeutics Names Dr. Armand Balboni as Chief Executive Officer Original press release here HALIFAX, Nova Scotia, December 2, 2019 – Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a clinical stage biopharmac...

Q3 2019 Share Price Performance

Q3 2019 Share Price Performance Healthcare Stocks – Choppy Stalling Pattern Continues In this blog post, the Bloom Burton equity research team summarizes the performance of the Canadian healthcare sector during 3Q-2019, and provides commentary on ...

Triumvira Immunologics Announces Fast Track Designation for Its First TAC T-Cell Therapeutic Product Candidate: TAC01-CD19

Triumvira Immunologics Announces Fast Track Designation for Its First TAC T-Cell Therapeutic Product Candidate: TAC01-CD19 Original press release here Designation Confirms Significant Unmet Need Remains in DLBCLNovember 07, 2019 07:00 AM Eastern Sta...

MindBeacon Group announces Series A follow-on investment round led by Green Shield Canada has exceeded $18 million

MindBeacon Group announces Series A follow-on investment round led by Green Shield Canada has exceeded $18 million Original press release here Investment will accelerate the company’s entrance into new markets and dramatic expansion of its digital...